| Methods | D: crossover C: unclear B: double WD: unclear J: 0‐1‐0 DU: unclear/3x2m (unclear whether washout)/unclear | |
| Participants | N: unclear/15 D: migraine with or without aura C: unclear F: unclear A: unclear DU: unclear S: unclear | |
| Interventions | P: 120 mg C1: Placebo C2: Verapamil 240 mg | |
| Outcomes | R: not reported F: 4.5 vs. 5.0 vs. 4.5 (sd not presented) AU: not reported HI: not reported AEs: unclear Dropouts‐AEs: not reported V: + vs. C1, 0 vs. C2 | |
| Notes | Small crossover study, available only as an abstract | |
| Risk of bias | ||
| Bias | Authors' judgement | Support for judgement |
| Allocation concealment (selection bias) | Unclear risk | B ‐ Unclear |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.